ZS Pharma readies NDA as competitor Relypsa's filing nears
This article was originally published in Scrip
Executive Summary
ZS Pharma will seek US and EU approvals for its hyperkalemia drug ZS-9 (sodium zirconium cyclosilicate) in 2015 based on two sets of positive Phase III results, but Relypsa is ahead of the game with plans to submit a new drug application (NDA) to the US FDA this year for its competing therapy patiromer.